217 related articles for article (PubMed ID: 12815476)
1. Stem cell transplantation for myelofibrosis: a report from two Canadian centers.
Daly A; Song K; Nevill T; Nantel S; Toze C; Hogge D; Forrest D; Lavoie J; Sutherland H; Shepherd J; Hasegawa W; Lipton J; Messner H; Kiss T
Bone Marrow Transplant; 2003 Jul; 32(1):35-40. PubMed ID: 12815476
[TBL] [Abstract][Full Text] [Related]
2. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM;
Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
[TBL] [Abstract][Full Text] [Related]
4. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
5. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
6. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis.
Snyder DS; Palmer J; Stein AS; Pullarkat V; Sahebi F; Cohen S; Vora N; Gaal K; Nakamura R; Forman SJ
Biol Blood Marrow Transplant; 2006 Nov; 12(11):1161-8. PubMed ID: 17085309
[TBL] [Abstract][Full Text] [Related]
9. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
10. Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients.
Shapira MY; Resnick IB; Bitan M; Ackerstein A; Samuel S; Elad S; Miron S; Zilberman I; Slavin S; Or R
Bone Marrow Transplant; 2004 Jul; 34(2):155-9. PubMed ID: 15235577
[TBL] [Abstract][Full Text] [Related]
11. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
12. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation.
Kim JG; Sohn SK; Kim DH; Baek JH; Lee KB; Min WS; Kim CC; Lee MH; Lee JJ; Chung IJ; Kim HJ; Lee JW
Bone Marrow Transplant; 2005 Mar; 35(5):489-95. PubMed ID: 15654350
[TBL] [Abstract][Full Text] [Related]
13. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
Fuji S; Kim SW; Fukuda T; Mori S; Yamasaki S; Morita-Hoshi Y; Ohara-Waki F; Heike Y; Tobinai K; Tanosaki R; Takaue Y
Biol Blood Marrow Transplant; 2008 May; 14(5):510-7. PubMed ID: 18410893
[TBL] [Abstract][Full Text] [Related]
14. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
15. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS
Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350
[TBL] [Abstract][Full Text] [Related]
16. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
18. Second allogeneic stem cell transplantation in myeloid malignancies.
Hartwig M; Ocheni S; Asenova S; Wiedemann B; Zabelina T; Ayuk F; Kabisch H; Erttmann R; Kröger N; Zander AR; Bacher U
Acta Haematol; 2009; 122(4):185-92. PubMed ID: 19887774
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Barosi G; Bacigalupo A
Curr Opin Hematol; 2006 Mar; 13(2):74-8. PubMed ID: 16456372
[TBL] [Abstract][Full Text] [Related]
20. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]